Multimodality-Integrated Deep Survival Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization: A Two-Center Collaborative Study

Social Science Research Network(2021)

Cited 0|Views25
No score
Abstract
Background & Aims: There is high heterogeneity in clinical outcome for patients with hepatocellular carcinoma (HCC) following transarterial chemoembolization (TACE) and the accurate survival prediction remains challenging. We aimed to develop and validate a deep survival approach for prognostic prediction in HCC with TACE. Methods: We built the survival models by integrating clinical variables, radiological identitifications, and an entire-volumetric radiomics signature in 200 training datasets using a series of survival analysis algorithms such as Cox extreme gradient boosting (Cox-XGBoost), Cox gradient boosting machine (Cox-GBM), deep Cox-Time, and stepwise Cox proportional hazard (Cox-PH) regression. Models were validated in two independent cohorts of 86 and 84 patients from two institutions, respectively. Concordance index (C-index) was used as the model performance metric. Results: A radiomics survival signature (Rad-S), constructed from 4,840 imaging features by Random survival forest and least absolute shrinkage and selection operator (LASSO) Cox analysis, demonstrated favorable prognostic performance with C-indexes of 0.610 to 0.663 in training and validation sets, respectively. Rad-S, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and neutrophil to lymphocyte ratio (NLR) were selected as top variables. Among all survival analysis algorithms and existing prognostic systems, the Cox-GBM model achieved the best prediction performance, with C-indexes of 0.687 to 0.763 in training and validation cohort, respectively; it also gave two risk strata with significant different clinical outcome. Conclusions: The newly designed Rad-S can be a favorable prognostic predictor of HCC with TACE. The Cox-GBM model integrating multimodal data can enhance the prognostic prediction, thus help personalized clinical management. Funding: None to declare. Declaration of Interest: None to declare. Ethical Approval: Ethics committee approval was granted by the local institutional ethics review board (protocol 2018-SR-025), and the requirement of written informed consent was waived. All procedures involving human participants were performed in accordance with the 1975 Helsinki declaration and its later amendments.
More
Translated text
Key words
hepatocellular carcinoma,transarterial chemoembolization,survival analysis,multimodality-integrated,two-center
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined